Pravin U. Dugel, MD, Ocular's Executive Chairman, President and CEO, will provide an update regarding the enrollment status ...

Updates on commercial insights and readiness plans for sozinibercept in wet AMDOpthea management to present in New York City on Tuesday, January ...

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today ...

Catch up on the clinical trial news, updates from the United States Food and Drug Administration (FDA), and company funding ...

Fintel reports that on January 7, 2025, Citigroup initiated coverage of EyePoint Pharmaceuticals (NasdaqGM:EYPT) with a Buy ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Global Bispecific Antibodies Market Size 2024: > USD 8.5 Billion Approved Bispecific Antibodies Yearly and Quarterly Sales ...

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

Pembrolizumab biosimilar is under clinical development by Formycon and currently in Phase III for Non-Small Cell Lung Cancer.

FYB-206 is under development for the treatment of malignant melanoma (black skin cancer) and non-small cell lung cancer. The drug candidate is a pembrolizumab biosimilar. It acts by targeting ...

ASD Specialty Healthcare LLC, trading as Besse Medical, has reached a $1.67 million settlement to resolve allegations of ...